https://www.thebodypro.com/category/fda-approved-hiv-medications/tag/news

The Latest

polypharmacy

This Week in HIV Research: The Menace of Concomitance

April 16, 2020: Anticoagulants and antiretroviral boosters; durvalumab doesn't impair antiretroviral therapy; cigarette use and oral HPV incidence; using common labs to predict Kaposi sarcoma risk.

By Barbara Jungwirth and Myles Helfand
taking a pill

Why Do Researchers Think HIV Meds Might Work Against COVID-19?

At least one such drug still holds that promise against coronavirus, but in general there’s little precedent for the same drug blocking different viruses.

By Tim Murphy
lab testing

This Week in HIV Research: The Frustrating Relativity of Efficacy

March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.

By Barbara Jungwirth and Myles Helfand
many one dollar bills

This Week in HIV Research: As Pill Burden Drops, Pill Cost Rises

Feb. 6, 2020: HIV medication costs outpace inflation; HIV's role in attenuating childhood vaccinations; the challenges of researching effects of medications during pregnancy; the need for localized HIV interventions in the U.S.

By Barbara Jungwirth and Myles Helfand
two elderly people sitting and looking at water

This Week in HIV Research: Our Attunement to Aging

Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.

By Barbara Jungwirth and Myles Helfand
hole in a fence

This Week in HIV Research: Removing Barriers to Better Care

Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.

By Barbara Jungwirth and Myles Helfand
young man looking at pill before taking it

FDA Approves Descovy for PrEP, but Only for Cisgender Men and Transgender Women

The FDA approved the fixed-dose combination of emtricitabine and tenofovir alafenamide for PrEP, but advocates hope to see more research on the HIV prevention drug's efficacy for receptive vaginal sex for cisgender women and transgender men.

By Sony Salzman
woman with doctor looking at prescription bottle

This Week in HIV Research: Every Prescription Can Use a Good Steward

Sept. 19, 2019: HIV antiretroviral stewardship plans in hospitals can save money -- and lives; demographic correlates of PrEP interruption; HIV and atrial fibrillation risk; cytopenias common, despite viral suppression.

By Barbara Jungwirth and Myles Helfand
Christoph D. Spinner

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

By Sony Salzman
Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

By Sony Salzman